Regulatory T Cell Production from Stem Cells Using Compound Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing regulatory T cells from pluripotent stem cells are inefficient, making it difficult to achieve high yields and industrial scalability.
Innovation Solution
A method involving the culture of pluripotent stem cell-derived CD4+ T cells in the presence of CDK8 and/or CDK19 inhibitors, TNFR2 agonists, mTOR inhibitors, and TGF-βR agonists to enhance the production of regulatory T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional culture methods are used for pluripotent stem cell-derived T cells, then the production process is simple, but the production efficiency and yield of regulatory T cells are low
Solution Approach 1:
The invention changes the chemical parameters of the culture system by introducing specific small molecule compounds (CDK8/19 inhibitor, mTOR inhibitor, TGF-βR agonist, TNFR2 agonist) to modify the culture conditions. This transforms the conventional simple culture method into an enhanced protocol with defined chemical additives that drive efficient regulatory T cell differentiation and expansion from pluripotent stem cells.
Solution Approach 2:
The invention creates a composite culture system by combining multiple small molecule compounds with distinct mechanisms of action. The culture medium becomes a composite formulation containing CDK8/19 inhibitor, mTOR inhibitor, TGF-βR agonist, and TNFR2 agonist, where each component contributes to different aspects of regulatory T cell development, achieving synergistic enhancement of production efficiency.
2Quantity of substance
If regulatory T cells are produced using existing methods, then the process can be maintained with current protocols, but high production yield and industrial scalability are difficult to achieve
Solution Approach 1:
The small molecule compounds in the culture system enable regulatory T cells to self-differentiate and self-expand from pluripotent stem cells without requiring complex ex vivo manipulation or multiple differentiation stages. The compounds create a culture environment that guides autonomous regulatory T cell development, simplifying the manufacturing process while achieving high yields suitable for industrial scale-up.
3Reliability
If FOXP3 expression is maintained in primary Treg using known compounds, then FOXP3 expression can be preserved, but the production efficiency remains insufficient for industrial applications
Solution Approach 1:
The invention merges multiple functional compounds into a single culture protocol: CDK8/19 inhibitor for FOXP3 expression maintenance, mTOR inhibitor for cell cycle control, TGF-βR agonist for differentiation signaling, and TNFR2 agonist for survival and expansion. This combination achieves both reliable FOXP3 expression and high production efficiency simultaneously, overcoming the limitation of using single compounds.
Data Source
AI summary
Disclosed are: a method for producing a cell population containing regulatory T cells, the method comprising (1) culturing a cell population containing pluripotent stem cell-derived CD4+ T cells in the presence of at least one substance selected from the group consisting of a CDK8 and/or CDK19 inhibitor, a TNFR2 agonist, an mTOR inhibitor, and a TGF-βR agonist; a cell population containing regulatory T cells obtained by the method; and a medicine containing the cell population containing regulatory T cells.